Edity Therapeutics and Aurigene Oncology Limited (AOL), a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited, a clinical-stage biotechnology company, announced a strategic collaboration to create novel cell therapy medicines for difficult-to-treat solid tumors.

Read more here.